How can we guide you?

Using a GPS. Not the car like one the BIOALVO’s proprietary one.

GPS D2 (from Global Platform Screening for Drug Discovery) is BIOALVO’s proprietary drug discovery platform based on in vivo assays performed in humanized yeasts. These are modified yeast strains that express the desired human therapeutic target and that have been engineered to possess a DNA sensor, responsive to the presence of this human therapeutic target, which is operable linked to a reporter gene. GPS D2 platform is customizable and available for partnering.

Based on different requisites of the targets under study BIOALVO developed different screening applications based on its GPS D2 technology, namely BLOCKADE and DISAGGREGATOR.

Yeast typifies a simple and representative cellular model of the physiological conditions in which the desired target is in the human body. Moreover, it is already scientifically proven that these organisms replicate fundamental cellular aspects that are relevant to neurodegenerative disorders. Additionally, yeast is an organism with very simple, fast and cheap growth conditions and amenable to HTS adaptation. With the proprietary BIOALVO’s yeast platforms, we can overcome the unspecific character of classical in vitro assays while, through its robotic adaptation, we can guarantee the same high throughput needs and low cost available from classical drug discovery programs.

Using our yeast based drug discovery platform we promptly detect major toxicity characteristics associated to the molecules screened, allowing an adequate strategic response that is reflected in reduction of costs associated with future development of condemned candidates. This technology, associated with secondary screening in human cell lines, expressing the desired targets, for hit/lead potency and toxicity confirmation, is a powerful platform indispensable for a fruitful and strong drug discovery programme.